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eCF309: a potent, selective and cell-permeable
mTOR inhibitor†‡
Craig Fraser, Neil O. Carragher and Asier Unciti-Broceta*
Kinase inhibitors capable of blocking the phosphorylation of protein substrates with high selectivity are
essential to probe and elucidate the etiological role of such molecules and their signalling pathways. By
addressing these biochemical questions in disease relevant cell-based and in vivo models, strong pharma-
cological evidence can be generated towards validating or disproving a target hypothesis. Pharmacological
studies can also provide fundamental information to identify appropriate biomarkers and rational drug
combination strategies and thereby facilitate clinical translation. However, due to the high number of
kinases encoded by the human genome (>500) and their highly conserved catalytic domains, the develop-
ment of such an elite class of inhibitors—a.k.a. high-quality chemical probes—represents a major
challenge. Through a ligand-based inhibitor design, focused library synthesis and phenotypic screening to
prioritize compounds with potent cell activity, we recently identified a cell cycle inhibitor with micromolar
potency that inhibits mTOR kinase activity. Following a rapid lead optimization campaign, we report the
development of eCF309, an mTOR inhibitor displaying low nanomolar potency both in vitro and in cells
and an excellent selectivity profile (S-score (35%) = 0.01 at 10 μM).
Introduction
The mechanistic or mammalian target of rapamycin (mTOR) is
a serine/threonine protein kinase that operates as the catalytic
subunit of two essential protein complexes called mTORC1 and
mTORC2.1 These complexes play a central role in several signal
transduction cascades, acting as sensors that integrate multiple
extracellular and intracellular signals to coordinate cell metabo-
lism, proliferation, survival and migration.1 Increased mTOR
signalling is found in many types of cancers, metabolic disor-
ders and neurodegenerative diseases.2,3 In cancer, such
augmented phosphorylative activity contributes to cancer patho-
genesis and chemoresistance mechanisms, and is typically in-
duced via genetic dysregulation of different upstream modula-
tors of mTORC1 and/or mTORC2 such as EGFR, PI3K, PTEN,
AKT, RAS or RAF.4–7 Interestingly, mTOR itself is rarely mutated
in cancer.8,9 Oncogenic activation of mTORC1/2 is identified by
studying the phosphorylation status of downstream molecules
such as 4E-BP1,4 AKT or P70-S6K and its substrate S6,10
which can assist in the selection of patients that are likely to
respond to mTOR-targeted therapy.11 Clinical evidence of in-
creased mTOR activity is found in approximately half of all
human malignancies,12 which make mTOR inhibition a very
attractive strategy to treat a wide range of cancers.
To date three drugs, rapamycin (or sirolimus), temsirolimus
and everolimus, have been clinically approved for medical use
as inhibitors of mTOR signalling.12,13 These compounds
belong to a family of chemically related macrolides known as
rapalogs that inhibit the kinase activity of the mTORC1 com-
plex through an allosteric interaction – involving the FKBP12
protein – that do not occur in the mTORC2 complex,14 thus
being active only in the former. However, the mTORC2 com-
plex is an important driver of cancer cell proliferation and
survival.12,13 Inhibitors that target the catalytic domain of
mTOR are then expected to induce superior anticancer activity
by the concurrent inhibition of both complexes.12
Via an iterative process consisting of ligand-based design
and phenotypic screening of focused chemical libraries,15 we
have recently discovered a novel pyrazolopyrimidine (5) with
high antiproliferative activity in cells (Scheme 1). Compound
5 displays submicromolar inhibition of mTOR (IC50 = 328 nM,
in biochemical assays) and selectivity over other family of
kinases. Herein we report the optimization of lead 5 into
the potent, highly selective mTOR inhibitor eCF309.
Results and discussion
Design, synthesis and screening of novel derivatives of lead
compound 5
The 4-aminopyrazoloĳ3,4-d]pyrimidine scaffold has been widely
explored for the development of bioactive small molecules
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and, particularly, for the design of ATP-competitive kinase in-
hibitors due to its resemblance to the structure of adenine.16
Medicinal chemistry campaigns on that scaffold have been
mainly directed at the C3 position of the heterocycle, which
have led to the discovery of inhibitors of different kinases,
mostly tyrosine kinases e.g. SRC, ABL, RET, PDGFRs, IGF1R,
VEGFRs or KIT,16–18 but also non-tyrosine kinases such as
PI3Ks and mTOR.7,18
Aiming to improve the potency of lead compound 5
against mTOR, we prepared a series of derivatives displaying
different acetal groups at the N1 position and by introducing
the C3 substituent of INK128 (now renamed as sapanisertib;
see structure in Table 2), a 4-aminopyrazoloĳ3,4-d]pyrimidine
analogue that is currently in clinical trials and reported to
have excellent potency against mTOR (IC50 = 1 nM, in vitro).
7
Following the synthesis route outlined in Scheme 2, new de-
rivatives 10–14 and lead compound 5 were prepared. Briefly,
the iodo-functionalized intermediates 4, 6 and 7 were
synthesised by alkylation of common intermediate 3 with the
corresponding alkyl bromide (Scheme 2). Compounds 10–14
were prepared by Suzuki–Miyaura cross-coupling with the
corresponding arylboronic acid/boronate in moderate to
excellent yields.
Based on the potent antiproliferative activity displayed by
lead compound 5 against HER2-positive MCF7 cells,15 the
novel analogues were also tested against this breast cancer
cell line. Besides compound 5, rapamycin, everolimus, INK128
and AZD2014 were tested as positive controls; all of which are
potent mTOR inhibitors either clinically-approved or in clini-
cal development.7,12,19 As previously discussed, rapamycin and
everolimus are inhibitors of the mTORC1 complex, while both
INK128 and AZD2014 are ATP-competitive mTOR inhibitors.
As shown in Fig. 1a, both compounds 10 and 11 showed
slightly superior antiproliferative properties than lead 5.
Remarkably, compounds 12–14 – all of which possess the
2-amino-1,3-benzoxazole moiety found at the C3 position of
INK128 – led to an activity increment of over two orders of
magnitude. 12, 13 and 14 exhibited EC50 values upon MCF7
breast cancer cell viability of 8.4, 7.6 and 6.7 nM, respectively,
and superior potency than AZD2014, a drug candidate cur-
rently under phase I and II clinical development across sev-
eral cancer indications.12 It is important to note that,
although rapamycin and everolimus exhibited very high anti-
proliferative properties (EC50 < 1 nM), their activity plateaus
at approximately 30% viability and thus did not result in the
complete elimination of MCF7 cell viability, even at the highest
dose (Fig. 1b). This is a well-established feature of mTORC1
inhibitors attributed to compensatory feedback mechanisms
due to the lack of inhibition of the mTORC2 complex.12
Scheme 1 Synthesis of mTOR inhibitor 5. a) Formamide, 180 °C, μw;
b) NIS, 180 °C, DMF, μw; c) NaH, bromoacetaldehyde diethyl acetal,
150 °C, μw; d) 1H-pyrroloĳ2,3-b]pyridine-5-boronic acid pinacol ester,
K2CO3, PdĲOAc)2, PPh3, dioxane/water (10 : 1), 120 °C, μw.
Scheme 2 Synthesis of novel derivatives 10–14. a)
Bromoacetaldehyde diethyl acetal, or 2-bromomethyl-1,3-dioxolane,
or bromoacetaldehyde dimethyl acetal, NaH, DMF, 150 °C, μw. b) 1H-
pyrroloĳ2,3-b]pyridine-5-boronic acid pinacol ester or 2-amino-1,3-
benzoxazole-5-boronic acid (9), K2CO3, PdĲOAc)2, PPh3, dioxane/water
(10 : 1), 120 °C, μw. c) BisĲpinacolato)diboron, K2CO3, PdĲOAc)2, PPh3,
dioxane/water (10 : 1), 120 °C, μw.
Table 1 IC50 values (in nM) calculated for 5, 12, 13 and 14 in a selection
of recombinant kinases. mTOR inhibition activity are highlighted in green
Kinase\hit
5 12 13 14
ABL 1210 >105 8630 9920
BLK >105 >105 >105 >105
FYN 1230 >105 >105 >105
KIT >105 >105 >105 >105
mTOR 328 15 59 25
PDGFRα >105 >105 >105 >105
RET 598 >105 >105 >105
SRC 2450 >105 >105 >105
YES 566 >105 >105 >105
PI3Kα ND 981 115 300
PI3Kβ ND >105 3850 5600
PI3Kγ ND 1340 302 99
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Kinase profiling of inhibitors 12–14
To determine the selectivity profile of the novel compounds,
the most potent derivatives (12–14) were screened against a
selected panel of recombinant kinases known to be inhibited
by 4-aminopyrazoloĳ3,4-d]pyrimidine derivatives. Changes on
kinase activity relative to DMSO were determined by measur-
ing 33P incorporation on its substrate (poly[Glu,Tyr]4 : 1) by
Reaction Biology Corp., USA. Compounds were tested at 10
different doses with 3-fold serial dilution starting from 10
μM and calculated IC50 values are shown in Table 1. Notably,
the novel compounds displayed high inhibition of mTOR,
several fold superior to that of the lead compound 5, and
good-to-excellent selectivity over other kinases, including
PI3Ks, a subfamily of kinases known to be targeted by most
mTOR kinase inhibitors.12 While derivative 12 (a.k.a. eCF309)
exhibited slightly lower antiproliferative potency against
MCF7 cells than 13 and 14, it induced the strongest inhibi-
tion of mTOR kinase activity (IC50 = 15 nM) and displayed
higher selectivity over PI3Ks. These results indicate that even
small modifications at the acetal group of the N1 position of
the ring can result in significant variations on the binding
properties of the inhibitor.
Encouraged by the high selectivity displayed by 12
against several kinases that are typically inhibited by
4-aminopyrazoloĳ3,4-d]pyrimidine derivatives, we extended the
characterization of its kinome profile by performing a single
dose inhibition study against 375 wild type and mutant
kinases (Reaction Biology Corp., USA). Compound 12 was
tested at 10 μM in duplicate and levels of enzymatic inhibi-
tion compared to DMSO (= 0% inhibition, see listed values in
the ESI‡). Averaged results were plotted with a 65% cut-off
value in a representation of the human kinome phylogenetic
tree using TREEspot™ from DiscoveRx (Fig. 2). Kinome pro-
filing identified only 5 hits, with an S-score = 0.01. mTOR
was the only protein inhibited at very high levels, with an
inhibition of its activity superior to 99%. In agreement with
previous assays, two lipid kinases PI3Kγ and PI3Kα (E545K)
were found among the hits with 85% and 65% inhibition,
respectively. The screening only identified two new hits:
DNA-PK, with 90%, and DDR1, with 77% inhibition. DNA-PK
is a serine/threonine protein kinase involved in the repair of
double-strand DNA and its inhibition has been proposed to
be beneficial to cancer therapy.20 Similarly, DDR1 (discoidin
domain receptor family member 1) is overregulated in several
cancers and has also been nominated as an oncology target.21
Although several kinase inhibitors have shown cross-
reactivity with mTOR, PI3K and DNA-PK,12 the inhibition of
DDR1 is an unusual feature. Overall, the study shows that 12
Fig. 2 Map of the human kinome inhibited by compound 12 at 10 μM.
Red circles denote inhibition of activity above 65%. The 5 interactions
mapped are DDR1, DNA-PK, mTOR, PI3Kα (E545K) and PI3Kγ. S-score
(35%) = 0.01.
Fig. 1 (a) EC50 values calculated after treating MCF7 cells with
compounds 5, 12–14, rapamycin, everolimus, INK128 and AZD2014 for
5 d (dose range: 0.3–1000 nM). Cell viability was determined using the
PrestoBlue® reagent. Error bars: ±SD from n = 3. (b) Dose response
curves of MCF7 cell viability under treatment with compound 12,


























































































Med. Chem. Commun. This journal is © The Royal Society of Chemistry 2015
(eCF309) is a potent mTOR inhibitor with remarkably low off-
target activities. According to the literature, the selectivity
profile of 12 is as good as or even better than that of any
other selective mTOR inhibitor reported to date.7,12,18,22,23
Western blot analysis
To verify that compound 12 inhibits both mTORC1 and
mTORC2 signalling in cells by inhibition of the mTOR cata-
lytic domain, we assessed the activation state (= phosphoryla-
tion) of downstream targets of both complexes by Western
blot. Phosphorylation levels of the p70 ribosomal S6 kinase 1
(P70S6K) and its substrate S6 were analysed as substrates of
mTORC1, and phospho-AKTY473 as an mTORC2 substrate.
MCF7 cells were seeded in a 6-well plate and grown until
80% confluence. The cells were serum starved (0.1% FBS) for
24 h before incubation with the inhibitor (compound 12 and
INK128, at varying concentrations) or DMSO (0.1% v/v) for 30
min, followed by 1 h of serum stimulation (10% FBS). The
cells were then lysed and analysed by protein immunoblot.
As shown in Fig. 3, compound 12 mediated a dose-dependent
reduction of the pP70S6K, pS6 and pAKT levels in MCF7
cells, achieving almost complete inhibition of the phosphory-
lation of these targets at 30 nM. The potency of compound
12 was about an order of magnitude lower than that of
INK128. These results are in good correlation with the IC50
values calculated in the biochemical assays and the pheno-
typic activities exhibited by both compounds.
Synthesis and biological screening of derivatives 17–19
Due to its potency and selectivity against mTOR, compound
12 was the most interesting derivative of the series. Nonethe-
less, the high activity displayed by compound 13 against both
PI3Ks and mTOR kinases prompted us to explore further
structure activity relationships. Maintaining the constrained
conformation provided by the 1,3-dioxolane at the N1 posi-
tion of compound 13, we studied the influence of removing
one or both oxygen atoms from the saturated 5-member ring.
Derivatives 17 and 18 were prepared as described in
Scheme 3. These novel compounds contained either a
methylcyclopentyl or 2-methyltetrahydrofuran group, respec-
tively, at the N1 position of the pyrazolopyrimidine ring.
Additionally, the aldehyde-containing compound 19 was syn-
thesized by acetal deprotection of compound 12 in acidic
conditions. Derivative 19 was prepared to evaluate whether
this potential metabolite of inhibitor 12 could still mediate
bioactivity in cells.
The antiproliferative properties of the new derivatives were
screened in a panel of 3 cancer cell lines: breast cancer MCF7
cells (as before), MDA-MB-231 (triple negative breast cancer)
and PC3 (prostate cancer). Cell viability was measured using
Fig. 3 Western blot of MCF7 cell lysates after treatment with
compound with 12 or INK128 at a dose range (3–100 nM). DMSO =
negative control.
Scheme 3 a) (Iodomethyl)cyclopentane or 2-(bromomethyl)
tetrahydrofuran, NaH, DMF, 150 °C, μw; b) 5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1,3-benzoxazol-2-amine, K2CO3, PdĲOAc)2,
PPh3, 1,4-dioxane/water (10 : 1), 120 °C, μw; c) TFA/water (1 : 1), 100 °C, μw.
Table 2 IC50 values (in nM) calculated for 12, 17 and 18 in a selection of
recombinant kinases. IC50 values provided for INK128 are taken from
published literature7
Kinase\hit
12 17 18 INK128
DDR1 2110 4.7 137 ND
DNA-PK 320 3 48 ND
mTOR 15 1.8 5 17
PI3Kα 981 3.5 44 2197
PI3Kβ >105 89 1120 52907
PI3Kγ 1340 5 77 2307
PI3Kδ 1840 7.3 149 2217
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the PrestoBlue® reagent and analysed by spectrofluorometry.
EC50 values were calculated for compounds 12, 17–19 and
INK128 using a 10-point half-log dose response study (0.3–
1000 nM). As shown in Fig. 4, compounds 12, 17 and 18
exhibited highly potent antiproliferative activity against all
three cell types. Notably, compound 17 was found to be the
most potent of all the compounds tested, with low nano-
molar EC50 values and superior activity than INK128.
The same trend in cell type sensitivity to treatment was
observed for the four derivatives (MCF7 > PC3 > MDA-MB-
231), thus suggesting that compounds 12, 17, 18 and INK128
target the same signalling pathway (PI3K-AKT-mTOR). These
results also provides information about the level of depen-
dence that each of these cell lines have on that pathway for
driving cell growth. In contrast, aldehyde derivative 19
showed no activity at the concentrations tested (ESI‡), indi-
cating that the acetal group exclusive to compound 12 is nec-
essary for the observed phenotypic effect and thus stable in
the cellular environment.
Phenotypic assessment of the antiproliferative properties of
derivatives 12, 17 and 18
In cancers, upregulated mTOR signalling contributes to
tumour cell proliferation through induction of cell cycle
progression.1–3 Indeed, previous studies in MCF7 cells by our
group have shown that the antiproliferative activity of lead
compound 5 was mediated by inhibition of the cell cycle.15
Therefore, it was important to assess whether the effect
Fig. 4 EC50 values calculated after treating MCF7, MDA-MB-231 and
PC3 cells with compounds 12, 17, 18 and INK128 (positive control) for
5 d (dose range: 0.3–1000 nM). Cell viability was determined using the
PrestoBlue® reagent. Error bars: ±SD from n = 3.
Fig. 5 (a) Relative distribution of MCF7, MDA-MB-231 and PC3 cell populations by cell cycle phase under treatment with compounds 12, 17, 18
and INK128 (dose range 0.3–1000 nM). G0/G1 phase is in black and other stages in shades of grey. Error bars: ±SD from n = 3. (b) Dose response
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exerted by the novel compounds 12, 17 and 18 was mediated
by cell cycle arrest. MCF7, MDA-MB-231 and PC3 cells were
treated with the 3 compounds and INK128 for 24 h using
DMSO (0.1%) as negative control. Afterwards, cells were fixed
with 4% paraformaldehyde and stained for DNA (Hoechst
33342), phospho-histone H3 (anti-pHH3 rabbit antibody with
AlexaFluor®-594 goat anti-rabbit IgG) and cyclin B1 (anti-
cyclin B1 antibody with AlexaFluor®-488 donkey anti-mouse
IgG). Cells were imaged using ImageXpress High Content Sys-
tem (Molecular Devices, USA) and phenotypic response quan-
tified automatically using MetaXpress image analysis soft-
ware. Cells were subsequently classified according to their
DNA content into G0/G1, S or G2 cell cycle phases. Mitotic
cells were classified according to their cyclin B1 or phospho-
histone H3 nuclear expression levels. As shown in Fig. 5a, all
the compounds, in all the cell types tested, caused G0/G1 cell
cycle arrest, as identified by the increase of the black popula-
tion in the charts. A similar trend to that seen in the viability
assays was found both in terms of compound potencies and
cell selectivity, with MCF7 being the most responsive cell type
and compound 17 being the most potent inhibitor. Notably,
the cell cycle inhibition activity of all the compounds were in
good correlation with the EC50 values calculated from the cell
viability assays. Analysis of the increment of the G0/G1 cell
population (Fig. 5b) showed that compounds 12 and 18 led
to similar phenotypic effect in all the cell lines. The G0/G1
cell cycle arrest mediated by INK128 is in agreement with the
published literature.7
Kinase profiling of inhibitors 17 and 18
To assess the targets likely involved in the bioactivity of 17
and 18, their kinase inhibition profile was studied on a
selected panel of recombinant kinases (Reaction Biology
Corp., USA). In accordance with the kinome profiling of com-
pound 12, kinase inhibition was evaluated for DDR1, DNA-
PK, PI3Ks and mTOR. Table 2 shows the IC50 values found
for compounds 12, 17 and 18, in comparison with the values
reported for INK-128.7 From the novel derivatives, 12
(eCF309) was found to be the most selective mTOR inhibitor.
After mTOR (with IC50 = 15 nM), the most inhibited kinase
was DNA-PK with an IC50 of 320 nM, thus displaying >20-fold
difference in activity. A gap greater than 65-fold was observed
for the rest of kinases, remarkable properties that make com-
pound 12 (eCF309) one of the mTOR inhibitors with higher
selectivity ever reported.12
Surprisingly, compound 18 showed 3-fold higher potency
against mTOR than derivative 12 and exhibited cross-
reactivity for the rest of the kinases tested. The similar pat-
terns shown by compound 12 and 18 in the cell viability and
cell cycle inhibition assays may be therefore related to a supe-
rior capacity of compound 12 to cross cell membranes. In
agreement with the cell assays, derivative 17 (a.k.a. eCF324)
showed a substantial increase in potency against mTOR rela-
tive to 12, with an IC50 value of 1.8 nM, similar to that
reported for compound INK-128.7 Interestingly, compound 17
was also highly potent (IC50 = 3–7 nM) against all the kinases
tested except PI3Kβ. While this dual PI3K/mTOR inhibitory
capability is not a novel feature,12 it is of relevance because it
has been associated with increased clinical efficacy in cancers
driven by the PI3K-AKT-mTOR pathway.18,23
Analysis of the kinase inhibition profile of 12, 17 and 18
indicates that the presence of oxygen atoms in the alkyl
group at the position N1 of the ring results in increased
mTOR selectivity. This, however, contrasts with the high
selectivity reported for INK128 over PI3Ks,7,24 a compound
that displays a small oxygen-free isopropyl group at N1.
Intrigued by this, we tested INK128 for internal ranking pur-
poses. Since the re-evaluation of the properties of INK128 is
out of the scope of this work, these results are not shown.
However, we feel the responsibility to implore scientists not
to ignore the off-target effects mediated by small molecule
inhibitors (e.g. INK128 over other related kinases such as
DNA-PK and PI3Kα) to ensure the rigor of their biological
conclusions upon target biology. This is particularly true for
inhibitors targeting highly conserved protein families.
Conclusions
The development of potent, selective and cell-permeable
small molecules that mediate dose-dependent inhibition of a
target protein in its natural environment is essential to eluci-
date the role of such prospective targets in normal and path-
ological settings. In clinical treatment, highly-selective inhibi-
tors are also important for the development of safer drug
combination therapies.25 Although many chemical probes are
currently available, customized chemical design of target se-
lectivity combined with careful characterization of their bio-
chemical and phenotypic properties is uncommon, even if that
is essential to confirm the accuracy of any biological conclu-
sions.26 This is particularly true in cancer, where multiple etio-
logical factors can be typically involved in carcinogenesis.27
In the search to optimize the cell potency and selectivity
against mTOR of a lead compound identified in previous
studies,15 we prepared and tested a series of novel
pyrazolopyrimidines following a straightforward 5-step syn-
thesis route. Phenotypic screening facilitated the identifica-
tion of several compounds exhibiting low nanomolar anti-
proliferative activity against breast and prostate cancer cells
via cell cycle arrest. Among the novel compounds, the most
potent derivative was 17 (eCF324), which displayed single-
digit nM potency against cancer cell proliferation via G0/1
phase cell cycle arrest and high in vitro inhibition of several
kinases including mTOR, PI3Ks, DNA-PK and DDR1. Remark-
ably, 17 (eCF324) demonstrated superior potency in cells
than INK128, an mTOR kinase inhibitor currently in clinical
development.24
From these series, the most interesting inhibitor for bio-
logical studies was compound 12 (eCF309). Kinase profiling
and Western blotting demonstrated that eCF309 is a potent
inhibitor of mTOR signalling (IC50 = 10–15 nM, both in vitro
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10 μM). Its remarkable potency in cells together with its rela-
tively simple synthesis, make compound eCF309 a highly
valuable probe for chemical biology and biomedicine. Nota-
bly, its aldehyde derivative 19 exhibited no activity, proving
that the acetal group of compound eCF309 is necessary for
the compound's bioactivity and stable in the cytoplasm.
Future studies will serve to evaluate whether this series of
mTOR inhibitors are also suitable for cancer treatment.
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